Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia
Restricted accessCase reportFirst published online September, 2012
Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia
Hepatotoxicity has been observed with several chemotherapy agents and combination regimens. Conventional treatment methods often include supportive care or observation. We report a case of a patient with noted transaminitis presumed secondary to chemotherapy, which did not resolve with supportive care but was shown to respond to milk thistle. The patient had an immediate decrease in liver function tests and showed decreased elevation in levels upon treatment with subsequent chemotherapy regimens. This case demonstrates the potential efficacy of milk thistle as a unique hepatoprotective agent.
LadasEKrollKJOberliesNH. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer2010; 116(2): 506–513.
2.
SchuppanDJiaJBrinkhausB. Herbal products for liver diseases: A therapeutic challenge for the new millennium. Hepatology1990; 30(4): 1099–1104.
3.
MannaSKMukhopadahyayAVanNT. Silymarin suppresses TNF-induced activation of NF-kappa B, c-jun N-terminal kinase and apoptosis. J Immunol1999; 163(12): 6800–6809.
4.
KaurGAtharMAlamMS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs2010; 28(5): 703–713.
5.
TokluHZTunali AkbayTVelioglu-OguncA. Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury. J Surg Res2008; 145(2): 214–222.
6.
ZiXGrassoAWKungHJ. Flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res1998; 58(9): 1920–1929.
7.
FloraKHahnMRosenH. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol1998; 93(2): 139–143.
8.
HeQKimJSharmaRP. Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. Toxicol Sci2004; 80(2): 335–342.
9.
DehmlowCErhardJDeGrootH. Inhibition of Kuppfer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology1996; 23(4): 749–754.
10.
VenkataramananRRamachandranVKomoroskiBJ. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucoronosyl transferase in human hepatocyte cultures. Drug Metab Dispos2000; 28(11): 1270–1273.
11.
BarzaghiNCremaFGattiG. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet1990; 15(4): 333–338.
12.
MascarellaS. Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res1993; 53(l): 98–102.
13.
FerenciPDragosicsBDittrichH. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol1989; 9(1): 105–113.
14.
AlbrechtMFrerickHKuhnU. Therapy of toxic liver pathologies with Legalon (in German). Z Klin Med1992; 47: 87–92.
15.
ZhouSLimLYChowbayB. Herbal modulation of P-glycoprotein. Drug Metabol Rev2004; 36(1): 57–104.
16.
WuJWLinLCTsaiTH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol2009; 121(2): 185–193.
BoariCBaldiERizzoliO. Silymarin in the protection against exogenous noxae. Drug Exp Clin Res1981; 7: 115–120.
21.
PalascianoGPortincasaPPalmieriV. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res Clin Exp1994; 55(5): 537–545.
22.
InvernizziRBernuzziSCianiD. Silymarin during maintenance therapy of acute promyelocytic leukemia. Haematologica1993; 78(5): 340–341.
